-

Zoetis to Participate in Upcoming Investor Conferences

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside chats at the following investor conferences.

  • Leerink Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET
  • Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 9:30 a.m. ET

Interested parties can access live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event.

About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

ZTS-COR
ZTS-IR

Contacts

Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study...

Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS’ capabilities into Zoetis’ Global Diagnostics portfolio enhances Zoetis’ reference laboratory services, delivering AI...

Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU anim...
Back to Newsroom